Merck
  • Home
  • Search Results
  • AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.

AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.

Gynecologic oncology (2014-08-12)
Yi Xie, Martin J Hicks, Stephen M Kaminsky, Malcolm A S Moore, Ronald G Crystal, Arash Rafii
ABSTRACT

Anti-angiogenesis therapies such as bevacizumab, the monoclonal antibody to vascular endothelial growth factor (VEGF), have been used against ovarian cancer, but transient and low peritoneal drug levels are likely a factor in treatment failure. We hypothesized that a single administration of adeno-associated virus (AAV)-mediated intraperitoneal expression of bevacizumab would direct persistent expression and suppress growth and metastasis of ovarian cancer. AAVrh.10BevMab, a rhesus serotype 10 adeno-associated viral vector coding for bevacizumab, was evaluated for the capacity of a single intraperitoneal administration to persistently suppress peritoneal tumor growth in an intraperitoneal model of ovarian carcinomatosis with human ovarian cancer cells in nude immunodeficient mice. The data demonstrates that AAVrh10.BevMab mediates persistent and high levels of bevacizumab in the peritoneal cavity following a single intraperitoneal administration in mice. In AAVrh10.BevMab treated A2780 human ovarian cancer-bearing mice, tumor growth was significantly suppressed (p<0.05) and the area of blood vessels in the tumor was decreased (p<0.04). Survival of mice with A2780 xenografts or SK-OV3 xenografts was greatly prolonged in the presence of AAVrh10.BevMab (p<0.001). Administration of AAVrh10.BevMab 4days after A2780-luciferase cell implantation reduced tumor growth (p<0.01) and increased mouse survival (p<0.0001). Combination of AAVrh10.BevMab with cytotoxic reagents paclitaxel or topotecan proved to be more effective in increasing survival than treatment with cytotoxic reagent alone. A single administration of AAVrh10.BevMab provides sustained and high local expression of bevacizumab in the peritoneal cavity, and significantly suppresses peritoneal carcinomatosis and increases survival in an ovarian cancer murine model.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
二甲基亚砜, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
二甲基亚砜, anhydrous, ≥99.9%
Sigma-Aldrich
二甲基亚砜, for molecular biology
Sigma-Aldrich
二甲基亚砜, ACS reagent, ≥99.9%
Sigma-Aldrich
二甲基亚砜, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
二甲基亚砜, suitable for HPLC, ≥99.7%
Sigma-Aldrich
二甲基亚砜, ReagentPlus®, ≥99.5%
Sigma-Aldrich
二甲基亚砜, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
二甲基亚砜, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
二甲基亚砜, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
草酸, 98%
Sigma-Aldrich
草酸, puriss. p.a., anhydrous, ≥99.0% (RT)
Sigma-Aldrich
二甲基亚砜, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
D-荧光素, synthetic
Sigma-Aldrich
二甲基亚砜, PCR Reagent
Sigma-Aldrich
草酸, ReagentPlus®, ≥99%
Sigma-Aldrich
二甲基亚砜 溶液, 50 wt. % in H2O
Sigma-Aldrich
草酸, purified grade, 99.999% trace metals basis
Supelco
二甲基亚砜, analytical standard
Supelco
二甲基亚砜, for inorganic trace analysis, ≥99.99995% (metals basis)
USP
二甲基亚砜, United States Pharmacopeia (USP) Reference Standard
Supelco
草酸 溶液, 0.1 M (COOH)2 (0.2N), eluent concentrate for IC
异氟烷, European Pharmacopoeia (EP) Reference Standard
二甲基亚砜, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
二甲基亚砜, puriss. p.a., dried, ≤0.02% water
碘克沙醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
D-荧光素, synthetic, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
8-Octanoyloxypyrene-1,3,6-trisulfonic acid trisodium salt, suitable for fluorescence, ≥90% (HPCE)